Abstract:Substance use disorders (SUDs) induce widespread molecular dysregulation in the nucleus accumbens (NAc), a brain region pivotal for coordinating motivation and reward. These molecular changes are thought to support lasting neural and behavioral disturbances that promote drug-seeking in addiction. However, different drug classes exert unique influences on neural circuits, cell types, physiology, and gene expression despite the overlapping symptomatology of SUDs. To better understand common and divergent molecular mechanisms governing SUD pathology, our goal was to survey cell-type-specific restructuring of the NAc transcriptional landscape in after psychostimulant or opioid exposure. We combined fluorescence-activated nuclei sorting and RNA sequencing to profile NAc D1 and D2 medium spiny neurons (MSNs) across cocaine and morphine exposure paradigms, including initial exposure, prolonged withdrawal after repeated exposure, and re-exposure post-withdrawal. Our analyses reveal that D1 MSNs display many convergent transcriptional responses across drug classes during exposure, whereas D2 MSNs manifest mostly divergent responses between cocaine and morphine, with morphine causing more adaptations in this cell type. Utilizing multiscale embedded gene co-expression network analysis (MEGENA), we discerned transcriptional regulatory networks subserving biological functions shared between cocaine and morphine. We observed largely integrative engagement of overlapping gene networks across drug classes in D1 MSNs, but opposite regulation of key D2 networks, highlighting potential therapeutic gene network targets within MSNs. These studies establish a landmark, cell-type-specific atlas of transcriptional regulation induced by cocaine and by morphine that can serve as a foundation for future studies towards mechanistic understanding of SUDs. Our findings, and future work leveraging this dataset, will pave the way for the development of targeted therapeutic interventions, addressing the urgent need for more effective treatments for cocaine use disorder and enhancing the existing strategies for opioid use disorder.

The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder

Shared and Divergent Transcriptomic Regulation in Nucleus Accumbens D1 and D2 Medium Spiny Neurons by Cocaine and Morphine

Dopamine D1 Receptor Gene Variation Modulates Opioid Dependence Risk by Affecting Transition to Addiction.

GENETIC STUDY: an Association of Prodynorphin Polymorphisms and Opioid Dependence in Females in a Chinese Population

Association between polymorphisms of DRD2 and DRD4 and opioid dependence: evidence from the current studies.

Genetic Variants Associated With Opioid Use Disorder

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice.

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) As a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment

Functional Impact of a Single-Nucleotide Polymorphism in the OPRD1 Promoter Region.

In vitro safety evaluation of dopamine D 3 R antagonist, R -VK4-116, as a potential medication for the treatment of opioid use disorder

Methylation and expression quantitative trait loci rs1799971 in the OPRM1 gene and rs4654327 in the OPRD1 gene are associated with opioid use disorder

Peripheral Biomarkers of Cognitive Response to Dopamine Receptor Agonist Treatment

Association of genetic variants in CYP3A5, DRD2 and NK1R with opioid overdose

A novel dopamine D2 receptor-NR2B protein complex might contribute to morphine use disorders

Pharmacological traits of delta opioid receptors: pitfalls or opportunities?

Analyzing Interaction of μ-, δ- and κ-opioid Receptor Gene Variants on Alcohol or Drug Dependence Using a Pattern Discovery-based Method.

Identification of 1,3,8-Triazaspiro[4.5]Decane-2,4-Dione Derivatives as a Novel δ Opioid Receptor-Selective Agonist Chemotype

Association Between Dopamine D2 Receptor Gene Polymorphisms and the Risk of Heroin Dependence

A functional polymorphism, rs6280, in DRD3 is significantly associated with nicotine dependence in European-American smokers.

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.